Pioglitazone, a Ppar-gamma Ligand, Exerts Cytostatic/cytotoxic Effects against Cancer Cells, That Do Not Result from Inhibition of Proteasome

Thiazolidinediones are oral antidiabetic agents that activate peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and exert potent antioxidant and anti-inflammatory properties. It has also been shown that PPAR-gamma agonists induce G0/G1 arrest and apoptosis of malignant cells. Some of these effects have been suggested to result from inhibition of proteasome activity in target cells. The aim of our studies was to critically evaluate the cytostatic/cytotoxic effects of one of thiazolidinediones (pioglitazone) and its influence on proteasome activity. Pioglitazone exerted dose-dependent cytostatic/cytotoxic effects in MIA PaCa-2 cells. Incubation of tumor cells with pioglitazone resulted in increased levels of p53 and p27 and decreased levels of cyclin D1. Accumulation of polyubiquitinated proteins within cells incubated with pioglitazone suggested dysfunction of proteasome activity. However, we did not observe any influence of pioglitazone on the activity of isolated proteasome and on the proteolytic activity in lysates of pioglitazone-treated MIA PaCa-2 cells. Further, treatment with pioglitazone did not cause an accumulation of fluorescent proteasome substrates in transfected HeLa cells expressing unstable GFP variants. Our results indicate that pioglitazone does not act as a direct or indirect proteasome inhibitor.

[1]  K. Stangl,et al.  Proteasome inhibitors: Poisons and remedies , 2008, Medicinal research reviews.

[2]  J. S. San Miguel,et al.  Bortezomib in multiple myeloma. , 2007, Best practice & research. Clinical haematology.

[3]  K. Kwon,et al.  Growth inhibition and apoptosis induced in human leiomyoma cells by treatment with the PPAR gamma ligand ciglitizone. , 2007, Molecular human reproduction.

[4]  Zhaoming Ye,et al.  Caspase‐8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132 , 2007, Cell biology international.

[5]  《中华放射肿瘤学杂志》编辑部.  Medline , 2001, Current Biology.

[6]  R. Scienza,et al.  Peroxisome Proliferator‐Activated Receptor γ in the Human Pituitary Gland: Expression and Splicing Pattern in Adenomas Versus Normal Pituitary , 2007, Journal of neuroendocrinology.

[7]  Q. Zhu,et al.  The ubiquitin–proteasome system regulates p53-mediated transcription at p21waf1 promoter , 2007, Oncogene.

[8]  H. Tai,et al.  Pioglitazone and Rosiglitazone Decrease Prostaglandin E2 in Non–Small-Cell Lung Cancer Cells by Up-Regulating 15-Hydroxyprostaglandin Dehydrogenase , 2007, Molecular Pharmacology.

[9]  L. Jeffrey Medeiros,et al.  Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma , 2007, Clinical Cancer Research.

[10]  F. Lacombe,et al.  Proteasome inhibitIon specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins , 2007, Cancer biology & therapy.

[11]  C. Chen,et al.  Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation. , 2007, Cancer research.

[12]  S. Fang,et al.  ER stress differentially regulates the stabilities of ERAD ubiquitin ligases and their substrates. , 2007, Biochemical and biophysical research communications.

[13]  R. Phipps,et al.  The Peroxisome Proliferator-Activated Receptor γ (PPARγ) Ligands 15-Deoxy-Δ12,14-Prostaglandin J2 and Ciglitazone Induce Human B Lymphocyte and B Cell Lymphoma Apoptosis by PPARγ-Independent Mechanisms1 , 2006, The Journal of Immunology.

[14]  C. Catapano,et al.  Cellular, Molecular Consequences of Peroxisome Proliferator- Activated Receptor-δ Activation in Ovarian Cancer Cells , 2006 .

[15]  A. Peri,et al.  Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells , 2006, British Journal of Cancer.

[16]  M. Kaminishi,et al.  Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues. , 2006, Journal of experimental & clinical cancer research : CR.

[17]  M. Korbonits,et al.  PPAR‐γ expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti‐proliferative effect of the glitazones is independent of the PPAR‐γ receptor , 2006, Clinical endocrinology.

[18]  Y. Tsao,et al.  Peroxisome proliferator–activated receptor-γ agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines , 2006, International Journal of Gynecologic Cancer.

[19]  D. Nowis,et al.  Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity , 2006, Oncogene.

[20]  Xiaofei Yu,et al.  Peroxisome proliferator-activated receptor in malignant diseases , 2006 .

[21]  K. Black,et al.  A Peroxisome Proliferator-activated Receptor-γ Agonist, Troglitazone, Facilitates Caspase-8 and -9 Activities by Increasing the Enzymatic Activity of Protein-tyrosine Phosphatase-1B on Human Glioma Cells* , 2006, Journal of Biological Chemistry.

[22]  J. Yun,et al.  Pioglitazone, a synthetic ligand for PPARγ, induces apoptosis in RB-deficient human colorectal cancer cells , 2006, Apoptosis.

[23]  E. Dmitrovsky,et al.  Uncovering residues that regulate cyclin D1 proteasomal degradation , 2006, Oncogene.

[24]  J. Roman,et al.  Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways , 2006, Molecular Cancer Therapeutics.

[25]  G. Giaccone,et al.  Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies , 2005, Cancer.

[26]  Fabrizio Mancinelli,et al.  Electromagnetic fields at mobile phone frequency induce apoptosis and inactivation of the multi‐chaperone complex in human epidermoid cancer cells , 2005, Journal of cellular physiology.

[27]  E. Gelmann,et al.  The ubiquitin-proteasome pathway and its role in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Harrison,et al.  Ciglitazone-induced cellular anti-proliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. , 2005, Cellular signalling.

[29]  C. Shapiro,et al.  Peroxisome Proliferator-Activated Receptor γ-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells , 2005, Molecular Pharmacology.

[30]  Q. Duh,et al.  Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. , 2005, Thyroid : official journal of the American Thyroid Association.

[31]  S. Kulp,et al.  Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. , 2005, Cancer research.

[32]  A. Gartel,et al.  The PPAR-? Agonist Pioglitazone Post-Trancriptionally Induces p21 in PC3 Prostate Cancer but Not in Other Cell Lines , 2005, Cell cycle.

[33]  J. Corbett,et al.  PPARγ ligands induce ER stress in pancreatic β-cells: ER stress activation results in attenuation of cytokine signaling , 2004 .

[34]  P. Kloetzel,et al.  The proteasome and MHC class I antigen processing. , 2004, Biochimica et biophysica acta.

[35]  N. Ishimura,et al.  Peroxisome proliferator‐activated receptor γ‐dependent and ‐independent growth inhibition of gastrointestinal tumour cells , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[36]  A. Sabichi,et al.  Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  S. Bernstein,et al.  Human multiple myeloma cells express peroxisome proliferator-activated receptor γ and undergo apoptosis upon exposure to PPARγ ligands , 2004 .

[38]  Q. Tong,et al.  Inhibitory effect of ubiquitin-proteasome pathway on proliferation of esophageal carcinoma cells. , 2004, World journal of gastroenterology.

[39]  D. Lane,et al.  Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo* , 2004, Journal of Biological Chemistry.

[40]  Philippe Vielh,et al.  Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators , 2004 .

[41]  G. Maira,et al.  The PPARγ ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines , 2004 .

[42]  P. Kloetzel.  Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII , 2004, Nature Immunology.

[43]  W. Hsueh,et al.  Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells , 2004, Oncogene.

[44]  P. Džubák,et al.  The Synthetic Ligand of Peroxisome Proliferator-Activated Receptor-γ Ciglitazone Affects Human Glioblastoma Cell Lines , 2004, Journal of Pharmacology and Experimental Therapeutics.

[45]  M. Korbonits,et al.  PPAR gamma expression in pituitary tumours , 2004 .

[46]  F. Chan,et al.  Effect of peroxisome proliferator activated receptor γ ligands on growth and gene expression profiles of gastric cancer cells , 2004, Gut.

[47]  P. Richardson,et al.  Bortezomib: a novel therapy approved for multiple myeloma. , 2003, Clinical advances in hematology & oncology : H&O.

[48]  A. Ciechanover,et al.  Oxidative stress‐related increase in ubiquitination in early coronary atherogenesis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  Jian Yu,et al.  Differential Apoptotic Response to the Proteasome Inhibitor Bortezomib (VELCADETM, PS-341) in Bax-Deficient and p21-Deficient Colon Cancer Cells , 2003, Cancer biology & therapy.

[50]  W. Roesler,et al.  Troglitazone reduces heat shock protein 70 content in primary rat hepatocytes by a ubiquitin proteasome independent mechanism. , 2003, Pharmacological research.

[51]  S. Safe,et al.  Peroxisome Proliferator-activated Receptor γ Agonists Induce Proteasome-dependent Degradation of Cyclin D1 and Estrogen Receptor α in MCF-7 Breast Cancer Cells , 2003 .

[52]  J. Lehmann,et al.  Printed in U.S.A. Copyright © 2002 by The Endocrine Society Divergent Effects of Selective Peroxisome Proliferator- Activated Receptor-�2 Ligands on Adipocyte Versus Osteoblast Differentiation , 2022 .

[53]  E. Dmitrovsky,et al.  Cyclin Proteolysis as a Retinoid Cancer Prevention Mechanism , 2001, Annals of the New York Academy of Sciences.

[54]  M. Wente,et al.  Peroxisome Proliferator-Activated Receptor γ Induces Pancreatic Cancer Cell Apoptosis , 2001 .

[55]  C. Kahn,et al.  Unraveling the mechanism of action of thiazolidinediones. , 2000, The Journal of clinical investigation.

[56]  T. Terada,et al.  PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. , 2000, International journal of oncology.

[57]  E. Brown,et al.  Expression of peroxisome proliferator‐activated receptors (PPARS) in human astrocytic cells: PPARγ agonists as inducers of apoptosis , 2000 .

[58]  S. Leung,et al.  Inhibition of proteasome function induced apoptosis in gastric cancer. , 2000, International journal of cancer.

[59]  S. Sato,et al.  p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  T. Chang,et al.  Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. , 2000, Cancer research.

[61]  M. Sporn,et al.  A New Ligand for the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ), GW7845, Inhibits Rat Mammary Carcinogenesis , 1999 .

[62]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[63]  T. Okumura,et al.  Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells , 1999 .

[64]  Rajnish A. Gupta,et al.  Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells , 1998 .

[65]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[66]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[67]  A. Wlodawer.  Proteasome: a complex protease with a new fold and a distinct mechanism. , 1995, Structure.

[68]  W. Baumeister,et al.  Structural features of the 26 S proteasome complex. , 1993, Journal of molecular biology.

[69]  D. Scudiero,et al.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.

[70]  O. Sezer,et al.  Molecular and clinical aspects of proteasome inhibition in the treatment of cancer. , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[71]  Y. Tsao,et al.  Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. , 2007, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[72]  C. Catapano,et al.  Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. , 2006, Neoplasia.

[73]  Renchi Yang,et al.  Peroxisome proliferator-activated receptor gamma in malignant diseases. , 2006, Critical reviews in oncology/hematology.

[74]  J. Roman,et al.  Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. , 2006, Molecular cancer therapeutics.

[75]  Y. Li,et al.  Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375 , 2006, Medical oncology.

[76]  K. Black,et al.  A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. , 2006, Journal of Biological Chemistry.

[77]  C. Shapiro,et al.  Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. , 2005, Molecular Pharmacology.

[78]  T. Okumura,et al.  Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells , 2004, International journal of cancer.

[79]  T. Grune.  Oxidative stress, aging and the proteasomal system , 2004, Biogerontology.

[80]  S. Bernstein,et al.  Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. , 2004, Clinical immunology.

[81]  J. Corbett,et al.  PPARgamma ligands induce ER stress in pancreatic beta-cells: ER stress activation results in attenuation of cytokine signaling. , 2004, American journal of physiology. Endocrinology and metabolism.

[82]  Philippe Vielh,et al.  Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. , 2004, Cancer treatment reviews.

[83]  S. Safe,et al.  Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. , 2003, Cancer research.

[84]  J. Lehmann,et al.  Divergent Effects of Selective Peroxisome Proliferator-Activated Receptor- (cid:1) 2 Ligands on Adipocyte Versus Osteoblast Differentiation , 2002 .

[85]  Béatrice Desvergne,et al.  PPAR expression and function during vertebrate development. , 2002, The International journal of developmental biology.

[86]  M. Wente,et al.  Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis. , 2001, Biochemical and biophysical research communications.

[87]  Bernhard O. Palsson,et al.  Cancer cell lines , 1999 .

[88]  M. Sporn,et al.  A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. , 1999, Cancer research.

[89]  A. Harris,et al.  The ubiquitin-proteasome pathway in cancer. , 1998, British Journal of Cancer.

[90]  K Tanaka,et al.  Structure and functions of the 20S and 26S proteasomes. , 1996, Annual review of biochemistry.